Risk stratification in stable coronary artery disease: Superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors

Coronary Artery Disease

Volumn 23, Issue 2, 2012, Pages 91-97

  Bode, Edmund ^a   Wuppinger, Thomas ^a   Bode, Thomas ^a   Alber, Hannes ^a   Ulmer, Hanno ^a   Pachinger, Otmar ^a   Mair, Johannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Gamma glutamyl transferase; High sensitivity C reactive protein; N terminal pro B type natriuretic peptide; Prognosis; Risk factor; stable coronary artery disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE;

AGED; ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STROKE; SURVIVAL RATE;

AGED; AUSTRIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84857234302     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32834f1165     Document Type: Review

References (24)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952. (Pubitemid 39208455)
2. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, et al. Risk factors and secondary prevention in women with heart disease: the heart and estrogen/progestin replacement study. Ann Intern Med 2003; 138:81-89. (Pubitemid 36222494)
3. Tate J, et al. on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810-824.
4. Mair P, Mair J, Bleier J, Hörmann C, Balogh D, Puschendorf B. Augmented release of brain natriuretic peptide during reperfusion of the human heart after cardioplegic cardiac arrest. Clin Chim Acta 1997; 261:57-68. (Pubitemid 27240263)
5. Goetze JP, Christoffersen C, Perko M. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17:1105-1107.
6. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874. (Pubitemid 36019640)
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
8. Lindahl B, Toss H, Siegbahn A, Venge P,Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343:1139-1147.
9. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 1997; 349:462-466. (Pubitemid 27077826)
10. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gammaglutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiologic investigation in a cohort of 163 944 Austrian adults. Circulation 2005; 112:2130-2137. (Pubitemid 41475806)
11. Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 2009; 136:80-85.
12. Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography - the Ludwigshafen risk and cardiovascular health study. Atherosclerosis 2010; 208:564-571.
13. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001; 38:263-355. (Pubitemid 32826505)
14. Paolicchi A, Minotti G, Tonarelli P. Gamma-glutamyl transpeptidase dependent iron reduction and LDL oxidation a potential mechanism in artherosclerosis. J Investig Med 1999; 47:151-160. (Pubitemid 129541449)
15. Paolicchi A, Emdin M, Ghiozeni E. Images in cardiovascular medicine - human atherosclerotic plaques contain gamma glutamyl transpeptidase enzyme activity. Circulation 2004; 109:1440. (Pubitemid 38387833)
16. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H, Pachinger O, et al. Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for the prediction of significant angiographic lesions in stable coronary artery disease. Heart 2009; 95:297-303.
17. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666-675. (Pubitemid 40239214)
18. März W, Tiran B, Seelhorst U, Wellnitz B, Bauersachs J, Winkelmann BR, Boehm BO. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen risk and cardiovascular health study. Clin Chem 2007; 53:1075-1083. (Pubitemid 46867524)
19. Omland T, Richards MA,Wergeland R, Vik-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol 2005; 95:24-28. (Pubitemid 40051107)
20. Huang PH, Lu TM,Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ. Usefulness of combined high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coronary Artery Dis 2008; 19:187-193.
21. Shlipak MGS, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008; 121:50-57.
22. predict mortality or detect acute ischemia in patients with coronary artery disease. Cardiology 2008; 109:249-257. (Pubitemid 351328920)
23. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. for the HOPE study investigators. Comparative impact of multiple biomarkers and NT-proBNP in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2006; 114:201-208. (Pubitemid 44297113)
24. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. for the AtheroGene investigators. Analysis of NT-proBNP and CRP for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene Study. Eur Heart J 2005; 26:241-249. (Pubitemid 40222362)